Known as a pulmonary embolism, the problem is described by research author Toru Shirakawa because ‘a significant, sometimes fatal, lung-related vascular disease characterized by sudden onset of symptoms such as chest pain or difficulty breathing. ‘[And] the condition is due to obstruction of the pulmonary arteries by bloodstream clots, generally formed in the leg vessels,’ he described in a news launch by the European Culture of Cardiology. Shirakawa is normally a public health research fellow in the department of social medication at Osaka University in Japan.I-SPY 2 is an fascinating and groundbreaking new medical trial model that will help scientists quickly and effectively check the most promising medicines in development for women with higher risk, quickly growing breast cancers-women for whom a noticable difference over standard treatment could dramatically switch the chances of survival. I-SPY is an initiative of the Biomarkers Consortium, a unique public-private partnership that includes the Food and Drug Administration , the National Institutes of Wellness , and main pharmaceutical businesses, led by the Foundation for the National Institutes of Health . ‘Tumor tumor profiling in the neoadjuvant setting is crucial to the success of the I-SPY 2 trial. Agendia is definitely uniquely positioned to be a portion of the Biomarker Consortium in this landmark study, and proud to become working side by side with a large number of visionary therapeutic analysis and companies centers,’ said Bernhard Sixt, Chief Executive Officer of Agendia.